FDA Approves Cancer Screening Test as First Device Under Parallel Review Pilot

by Ropes & Gray LLP
Contact

On August 11, 2014, the Food and Drug Administration (FDA) issued a premarket approval (PMA) for Exact Sciences’ Cologuard, a colorectal cancer screening test, and the Centers for Medicare & Medicaid Services (CMS) issued a proposed national coverage determination (NCD) for Cologuard on the same day. Cologuard is the first device to be approved under CMS and FDA’s Pilot Program for Parallel Review of Medical Products (the Pilot Program), a voluntary program for companies to coordinate with FDA and CMS to reduce the time between FDA marketing approval and NCDs.

Although begun in 2011 with much fanfare, and extended for an additional two years in December 2013, no devices had successfully navigated the process.1 Because participation is confidential, it is difficult to know exactly how many devices have joined the pilot. Exact Sciences is one of few companies that has publicly announced its participation in the program. This result may encourage additional companies to consider the advantages of this combined path for FDA approval and Medicare coverage of a new device. The direct impact of this development is likely to be limited (for the reasons discussed below), but it is nonetheless an important milestone and could put some momentum behind efforts to coordinate FDA and CMS reviews.

There are several reasons that Cologuard’s approval and NCD may have limited implications. To begin with, most medical devices enter the U.S. market under a 510(k) substantial equivalence clearance, rather than a new-device PMA. In addition, few devices go through the NCD process. NCDs, which affect Medicare payments nationally, carry significant costs for the manufacturer, as well as significant consequences from an adverse decision. Instead, many manufacturers seek local coverage determinations (LCDs), which are coverage decisions made at the discretion of local Medicare contractors in the absence of an NCD. Finally, the Pilot Program is a limited program with few participants. When the Pilot Program launched in October 2011, FDA stated that the Pilot Program expected to accept only three to five device candidates per year.

The key issue addressed by the Pilot Program is the timing of CMS involvement. The Pilot Program does not affect review standards for device approval by FDA or for a coverage determination by CMS. The Pilot Program was created as a response to the lag time that exists between when FDA permits a device to be legally marketed and when CMS is able to make a national coverage decision. Generally, medical device review by FDA and CMS proceeds serially; FDA first determines whether the device meets applicable safety and effectiveness standards. After FDA approval or clearance, the company seeks coverage from third-party payors, including CMS, who determine the payment rate for the product. This process can be inefficient for several reasons. Administratively, materials submitted for FDA review are generally not available to CMS or other payors. More fundamentally, CMS is concerned with issues that may not have been emphasized by FDA for device approval (e.g., community and home use; generalizability of results to other populations; incremental clinical utility compared to currently available technology), which may require device sponsors to perform additional clinical trials.

Cologuard is a colorectal cancer screening test that evaluates DNA in stool for specific DNA markers and fecal hemoglobin using a proprietary analytic algorithm. Under CMS’s coverage decision, CMS will cover Cologuard once every three years for beneficiaries aged 50-85 years who are asymptomatic and at average risk of developing colorectal cancer. CMS is currently seeking comments on its proposed coverage decision.

Results from Exact Sciences’ pivotal trial with 9,899 patients comparing Cologuard to fecal immunochemical tests was published online in the New England Journal of Medicine on March 19, 2014. On March 27, 2014, FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Cologuard demonstrated safety, effectiveness and a favorable risk benefit profile.

1 76 Fed. Reg. 62808, 63809 (October 11, 2011); 78 Fed. Reg. 76628 (Dec. 18, 2013). 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Written by:

Ropes & Gray LLP
Contact
more
less

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.